



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-087/S-036

Hoffmann-La Roche, Inc.
Attention: Duane L. Voss
Program Director, Drug Regulatory Affairs
340 Kingsland Street
Nutley, NJ 07110-1199

Dear Ms. Voss:

Please refer to your supplemental new drug application dated August 29, 2006, received August 30, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Tamiflu® (oseltamivir phosphate) Capsules.

This "Changes Being Effected in 30 days" supplemental new drug application provides for an alternate blister packaging site for the drug product, Hoffmann-La Roche, Inc., facilities in Nutley, New Jersey (Roche Nutley).

We completed our review of this supplemental new drug application. This supplement is approved.

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Valerie Jimenez, MS, Senior Regulatory Project Manager, at (301) 796-1345.

Sincerely,

{See appended electronic signature page}

Hasmukh Patel, Ph.D.
Branch Chief
Branch 8, Division of Post-Marketing Evaluation
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Hasmukh Patel
2/27/2007 12:12:03 PM